Botensilimab | Interleukin Related interleukin-related.com

Product Name :
Botensilimab

Search keywords :
Botensilimab

drugId :
null

Target Vo:
Cytotoxic T-Lymphocyte-Associated Antigen 4

Target Vo Short Name :
CTLA4

Moa_Name:
Antibody-dependent cell-mediated cytotoxicity (ADCC) effects

First Approval Country :

First Approval Date Filter:
null

Origin Company_Name :
Agenus Inc

Active Company_Name :
Agenus Inc

Active Indication_Name:
Microsatellite Instability

In Active Indication_Name:
Melanoma

Termination Status :

China Termination Status :

Highest Status:
Phase 3 Clinical

China Highest Status:

Antibodies are immunoglobulins secreted by effector lymphoid B cells into the bloodstream. Antibodies consist of two light peptide chains and two heavy peptide chains that are linked to each other by disulfide bonds to form a “Y” shaped structure. Both tips of the “Y” structure contain binding sites for a specific antigen. Antibodies are commonly used in medical research, pharmacological research, laboratory research, and health and epidemiological research. They play an important role in hot research areas such as targeted drug development, in vitro diagnostic assays, characterization of signaling pathways, detection of protein expression levels, and identification of candidate biomarkers.
Related websites: https://www.medchemexpress.com/antibodies.html
Popular product recommendations:
Phospho-ERK1/2 (Thr202/Tyr204)/(Thr185/Tyr187) Antibody
Hsp70 Antibody (YA359)
eIF4G1 Antibody: eIF4G1 Antibody is a non-conjugated and Rabbit origined polyclonal antibody about 175 kDa, targeting to eIF4G1. It can be used for WB,IHC-P,ICC/IF assays with tag free, in the background of Human, Mouse, Rat.

Author: Interleukin Related

Related Posts